Coronary Artery Disease: Causes, Symptoms, Diagnosis, and Treatment

What Is Coronary Artery Disease?

Coronary artery disease is the slow accumulation of cholesterol-rich plaque inside the walls of the coronary arteries, the vessels that deliver oxygenated blood directly to heart muscle. Over years, this process, called atherosclerosis, hardens the arterial wall and narrows the channel through which blood can flow. When a plaque ruptures, the resulting clot can block blood flow entirely, triggering a myocardial infarction.

The ACC/AHA 2019 guideline defines atherosclerotic cardiovascular disease (ASCVD) as "coronary heart disease, stroke, and peripheral arterial disease, all presumed to be of atherosclerotic origin," making CAD the centerpiece of the broader ASCVD risk framework. [1]

Atherosclerosis begins earlier than most people expect. Autopsy studies of young US soldiers killed in the Korean War found visible fatty streaks in coronary arteries in men with a mean age of 22, decades before any clinical event would have appeared. The disease is both common and insidious. The CDC reported 375,476 US deaths attributable to coronary heart disease in 2021, roughly one death every 84 seconds. [2]

How Atherosclerotic Plaque Forms and Progresses

Plaque does not appear overnight. The process starts when low-density lipoprotein cholesterol (LDL-C) particles penetrate a damaged endothelial surface and become oxidized. Macrophages engulf the oxidized LDL to form foam cells, which accumulate into a fatty streak. Over time, smooth muscle cells migrate into the region, a fibrous cap forms, and the plaque grows.

Stable plaques have thick fibrous caps and cause predictable exertional angina by limiting flow. Vulnerable plaques have thin caps and a large lipid core, prone to sudden rupture. Rupture exposes thrombogenic material, activating platelets and the coagulation cascade within seconds.

The INTERHEART study (N=15,152 cases across 52 countries) identified nine modifiable risk factors that collectively accounted for over 90% of population-attributable risk for a first myocardial infarction: abnormal lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial stress, low daily fruit and vegetable consumption, lack of physical activity, and excess alcohol. [3] Each factor adds to plaque burden independently, and their co-occurrence, common in metabolic syndrome, accelerates progression substantially.

Hypertension Stage 1 vs. Stage 2: Why the Distinction Matters for CAD

Hypertension contributes directly to coronary plaque by increasing mechanical shear stress on the endothelium, promoting inflammation, and accelerating arterial stiffening. The 2017 ACC/AHA High Blood Pressure Guideline redefined thresholds significantly.

Stage 1 hypertension is a systolic blood pressure (SBP) of 130-139 mmHg or a diastolic blood pressure (DBP) of 80-89 mmHg. Stage 2 hypertension is an SBP of 140 mmHg or higher, or a DBP of 90 mmHg or higher. [4] This downward shift from the previous 140/90 mmHg Stage 1 threshold reclassified an estimated 31 million additional Americans as hypertensive, most of them younger adults without other risk factors.

For CAD specifically, the separation matters because risk is not flat between the two stages. The SPRINT trial (N=9,361) tested whether targeting SBP below 120 mmHg versus below 140 mmHg reduced cardiovascular events. The intensive arm achieved a 25% relative reduction in the primary composite endpoint of myocardial infarction, acute coronary syndrome, stroke, heart failure, and cardiovascular death, although it also produced higher rates of acute kidney injury and syncope. [5] That trade-off shapes how clinicians decide when to add pharmacotherapy to lifestyle modification alone.

For Stage 1 hypertension without additional ASCVD risk factors, the 2019 ACC/AHA prevention guideline recommends lifestyle intervention first: the DASH diet, sodium reduction to below 2 to 300 mg per day, 150 minutes per week of moderate-intensity exercise, and a target weight loss of 1 kg per 2.2 lbs reduction in SBP achieved. Pharmacotherapy is added when the 10-year ASCVD risk score exceeds 10%, or if a second risk condition such as diabetes or CKD is present.

Stage 2 hypertension calls for medication regardless of risk score. First-line agents include thiazide diuretics (chlorthalidone 12.5-25 mg daily is preferred over hydrochlorothiazide for its longer half-life), ACE inhibitors or ARBs, and dihydropyridine calcium channel blockers such as amlodipine 5-10 mg daily. Beta-blockers are reserved for patients with concurrent CAD, heart failure, or arrhythmia rather than used as primary antihypertensives.

Hyperlipidemia: LDL-C Targets and Statin Evidence

Elevated LDL-C is the single most studied causal driver of atherosclerosis. Mendelian randomization studies confirm that lifetime LDL-C exposure determines atherosclerotic burden in a dose-dependent, time-integrated fashion: every 1 mmol/L (~39 mg/dL) reduction in LDL-C reduces major cardiovascular events by approximately 22% per year of treatment. [6]

Statin therapy remains the pharmacological cornerstone of lipid management. The JUPITER trial randomized 17,802 apparently healthy adults with LDL-C below 130 mg/dL but elevated high-sensitivity CRP (hsCRP above 2 mg/L) to rosuvastatin 20 mg or placebo. The rosuvastatin arm saw a 44% reduction in the composite endpoint of MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death at a median follow-up of 1.9 years, with the trial halted early for efficacy. [7]

The 2018 ACC/AHA cholesterol guideline stratifies patients into four benefit groups and sets LDL-C targets accordingly. [8] Patients with established ASCVD (a "very high-risk" sub-group that includes a second major event or multiple high-risk conditions) should achieve LDL-C below 70 mg/dL; if maximally tolerated statin therapy does not reach that target, ezetimibe 10 mg daily is added first, then a PCSK9 inhibitor (evolocumab or alirocumab) if still not at goal.

The FOURIER trial (N=27,564) tested evolocumab on top of statin therapy. Over a median of 2.2 years, evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut the composite cardiovascular risk by 15% relative to placebo. [9] PCSK9 inhibitors are now guideline-endorsed for very high-risk patients not meeting LDL-C targets on statins plus ezetimibe.

Beyond LDL-C, triglycerides above 500 mg/dL require urgent treatment with fibrates (fenofibrate 145 mg daily) or prescription omega-3 fatty acids (icosapentaenoic acid 4 g daily as icosapent ethyl). The REDUCE-IT trial (N=8,179) showed icosapent ethyl reduced the primary composite endpoint by 25% in statin-treated patients with elevated triglycerides (150-499 mg/dL) and established ASCVD or diabetes. [10]

Metabolic Syndrome and Its Amplifying Effect on CAD Risk

Metabolic syndrome is not a single disease. It is a cluster of five measurable abnormalities that, when three or more are present together, confers a risk of cardiovascular events roughly two times higher than having none of them.

The five criteria per the harmonized IDF/NHLBI/AHA 2009 joint statement are: (1) waist circumference above 102 cm in men or above 88 cm in women, (2) triglycerides at or above 150 mg/dL, (3) HDL-C below 40 mg/dL in men or below 50 mg/dL in women, (4) blood pressure at or above 130/85 mmHg, and (5) fasting glucose at or above 100 mg/dL. [11]

NHANES data from 2011 to 2016 placed metabolic syndrome prevalence at 34.7% of US adults, with rates rising with age to over 50% in adults 60 and older. Each component independently accelerates atherosclerosis, but their combination creates what researchers call "atherogenic dyslipidemia," a phenotype characterized by small, dense LDL particles, high triglycerides, and low HDL-C, which is more coronary-toxic than elevated total LDL-C alone.

GLP-1 receptor agonists have recently changed the metabolic syndrome conversation. The SELECT trial (N=17,604), published in 2023, randomized adults with established cardiovascular disease and obesity (BMI of 27 or higher, no prior diabetes) to semaglutide 2.4 mg weekly versus placebo. Semaglutide reduced the primary endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% over a mean follow-up of 34 months, with benefits appearing independent of weight loss magnitude. [12] This positions GLP-1 receptor agonists as tools that address multiple metabolic syndrome components simultaneously: weight, blood pressure, glucose, and inflammatory markers.

Coronary Artery Disease Symptoms: Stable Angina to Acute MI

Symptoms exist along a spectrum. Stable angina produces predictable chest pressure or tightness on exertion, typically lasting 2-10 minutes, relieved by rest or sublingual nitroglycerin within 3-5 minutes. Unstable angina occurs at rest or with minimal exertion, lasts longer, and signals an acutely vulnerable plaque.

Chest pain is classic but not universal. Women, older adults, and people with diabetes more often present with atypical symptoms: jaw pain, left arm heaviness, nausea, dyspnea, or unexplained fatigue. The AHA's 2016 scientific statement on chest pain in women notes that nearly 50% of women having an MI describe no chest pain at all. [13]

Silent ischemia, ST-segment depression on stress testing without symptoms, is common in people with diabetes because of autonomic neuropathy. These patients may have significant CAD without ever experiencing angina, making screening in high-risk populations especially important.

Diagnosis: From Risk Scoring to Imaging

Clinical evaluation begins with the 10-year ASCVD risk calculator (Pooled Cohort Equations), which uses age, sex, race, total cholesterol, HDL-C, SBP, antihypertensive use, diabetes status, and smoking history to estimate 10-year risk. A score above 7.5% places a patient in the "intermediate" group where statin therapy is generally recommended; above 20% is "high risk."

Beyond risk scoring, several diagnostic tools exist:

Resting ECG. Detects prior MI (Q waves), left ventricular hypertrophy, or conduction abnormalities. Sensitivity for CAD alone is poor.

Exercise stress test. ACC/AHA class I indication for patients with intermediate pre-test probability of obstructive CAD who can exercise and have an interpretable ECG. ST-segment depression of 1 mm or more at standard leads during peak exercise is a positive result, though specificity is only about 70%.

Coronary artery calcium (CAC) scoring. A non-contrast CT scan assigns a CAC score (Agatston units). A score of zero carries a very low 10-year event rate and may allow deferral of statin therapy in borderline-risk patients; a score above 300 reclassifies patients to high risk. The 2019 ACC/AHA prevention guideline gives CAC scoring a class IIa recommendation when the statin decision is uncertain. [1]

Coronary CT angiography (CCTA). The PROMISE trial (N=10,003) compared CCTA to functional testing in stable chest pain and found similar rates of major cardiovascular events but higher rates of guideline-directed preventive medication use in the CCTA arm, suggesting it can improve risk-factor management. [14]

Invasive coronary angiography. The reference standard for defining stenosis severity. Lesions with 70% or greater diameter stenosis are typically revascularized; lesions between 40% and 70% stenosis are evaluated by fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) to determine hemodynamic significance before PCI.

Heart Failure with Preserved Ejection Fraction (HFpEF) as a CAD Sequela

Heart failure with preserved ejection fraction is defined as symptomatic heart failure (breathlessness, edema, reduced exercise tolerance) with a left ventricular ejection fraction (LVEF) of 50% or higher. It accounts for roughly half of all heart failure hospitalizations and has a 5-year mortality rate comparable to many cancers.

CAD contributes to HFpEF through two paths. First, repeated ischemic episodes cause patchy fibrosis that stiffens the myocardium without killing enough cells to reduce LVEF. Second, the shared risk factors of hypertension and metabolic syndrome drive diastolic dysfunction independently of overt ischemia.

Treatment of HFpEF remained evidence-poor for two decades. That changed with the EMPEROR-Preserved trial (N=5,988), which randomized patients with LVEF above 40% and NYHA class II-IV symptoms to empagliflozin 10 mg daily versus placebo. Empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 21% (P<0.001), the first drug to show clear benefit in this population. [15] The ACC/AHA 2022 heart failure guideline now gives empagliflozin and dapagliflozin a class IIa recommendation for HFpEF.

SGLT2 inhibitors achieve this partly through osmotic diuresis (reducing preload), partly through direct myocardial effects on sodium-hydrogen exchange, and likely through weight reduction averaging 2-3 kg in trials. For patients with HFpEF and concurrent CAD, the combination of a statin, a renin-angiotensin agent, and an SGLT2 inhibitor addresses multiple mechanisms simultaneously.

Evidence-Based Treatment Framework

The following four-layer treatment framework organizes CAD management by intervention type, matching each layer to the relevant evidence base.

Layer 1: Lifestyle foundation. The Lyon Diet Heart Study assigned post-MI patients to a Mediterranean diet versus a prudent Western diet. At 46 months, the Mediterranean group had a 72% relative reduction in recurrent MI and cardiac death. The diet emphasized alpha-linolenic acid (ALA) from canola oil and walnuts, legumes, fruits, and vegetables, with limited red meat. Smoking cessation alone reduces cardiovascular mortality by 36% within 2-3 years of quitting, per meta-analysis of 20 cohort studies. [16]

Layer 2: Pharmacotherapy. Aspirin 81 mg daily is class I for secondary prevention in established CAD; its role in primary prevention is now class IIb or lower given bleeding risk. High-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) are the anti-atherogenic backbone for LDL-C reduction. Beta-blockers (metoprolol succinate, carvedilol) reduce mortality post-MI and control angina. ACE inhibitors or ARBs reduce remodeling and mortality in patients with reduced ejection fraction. Dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor (ticagrelor 90 mg twice daily or clopidogrel 75 mg daily) is standard for 12 months after a drug-eluting stent.

Layer 3: Revascularization when appropriate. PCI with drug-eluting stents is preferred for single-vessel or two-vessel disease, while CABG is preferred for left main disease, three-vessel disease with reduced ejection fraction, or diabetes with multivessel disease. The SYNTAX trial (N=1,800) demonstrated superior 5-year outcomes with CABG over PCI for complex three-vessel CAD as measured by the SYNTAX score. [17]

Layer 4: Cardiac rehabilitation. A 2016 Cochrane review of 63 randomized trials (N=14,486) found exercise-based cardiac rehabilitation reduced cardiovascular mortality by 26% and all-cause hospitalization by 18% versus usual care alone. [18] Structured programs run 36 sessions over 12 weeks and combine aerobic training, resistance exercise, dietary counseling, and psychosocial support.

Monitoring, Follow-Up, and Long-Term Goals

After an acute coronary syndrome or revascularization, lipid panels are checked at 4-6 weeks and again at 3 months to confirm LDL-C is below 70 mg/dL. Blood pressure is monitored at every visit with a target below 130/80 mmHg per the 2019 ACC/AHA guideline. [1] HbA1c is assessed every 3 months in patients with diabetes and at least annually in those with metabolic syndrome.

Patients with CAD and diabetes who have not achieved HbA1c targets should have their regimen reviewed for addition of a GLP-1 receptor agonist or SGLT2 inhibitor given their proven cardiovascular benefits beyond glucose lowering. The LEADER trial (N=9,340) found liraglutide reduced the primary MACE composite by 13% versus placebo over 3.8 years in high-cardiovascular-risk patients with type 2 diabetes. [19]

Annual influenza vaccination reduces cardiovascular hospitalizations by approximately 18% in CAD patients, a benefit confirmed in a 2013 Cochrane review of four randomized trials. Serial CAC imaging is not routinely recommended for monitoring because it does not change established management, but a repeat scan 5-7 years after a zero baseline score may reclassify borderline-risk patients as risk evolves with age.